If subsequently approved, Entresto will be the first and only approved therapy for the treatment of symptomatic chronic heart failure patients aged 1 to <18 years in the European Union Pediatric heart failure is an important cause of childhood morbidity and mortality – up to a third of all pediatric […]
Coronary/Structural Heart
Pulnovo Medical Announces 3-Year Follow-up Results from PADN-5 at THT 2023, The Medical Device Maker Breaks New Ground in Heart Failure Treatment
SHANGHAI, March 28, 2023 /PRNewswire/ — Pulnovo Medical Limited, a globally recognized OTM platform, announced the results from its PADN series study during the Late-Breaking Clinical Science (LBCS) session of the second Technology and Heart Failure Therapeutics (THT 2023), with the presentation of its follow-up findings from PADN-5 study. As the first […]
Saranas Reaches Midpoint for Enrollment in Clinical Trial Assessing the Utility of Early Bleed Detection in Patients Undergoing Mechanical Circulatory Support
SAFE-MCS Examines the Impact of the Early Bird® Bleed Monitoring System on Reducing Bleeding Complications in Patients Undergoing High Risk PCI with Mechanical Circulatory Support HOUSTON–(BUSINESS WIRE)–Saranas, Inc. announced today that it has reached the midpoint for enrollment in SAFE-MCS, a multi-center, single arm, open-label clinical trial evaluating the safety […]
Daxor Corporation Announces Significant Expansion With Five Hospitals Implementing Its BVA-100® Blood Volume Diagnostic for Heart Failure Patients
Oak Ridge, TN, March 27, 2023 (GLOBE NEWSWIRE) — Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces five new hospitals have implemented the Company’s BVA-100 blood volume diagnostic for clinical use to guide fluid management in heart failure patients during the first quarter of 2023. The addition […]
Cytokinetics Releases Inaugural Corporate Responsibility Report
Report Highlights Company Commitment to Patient Centricity, Sustainability, Ethics, Diversity, Equity and Inclusion SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the release of its inaugural Corporate Responsibility Report, outlining the Company’s commitment to social and environmental responsibility, ethics and governance and patient and […]
NEW DATA SHOW REMOTE MONITORING TECHNOLOGY LIKE ABBOTT’S CARDIOMEMS HELPS IMPROVE SURVIVAL IN HEART FAILURE PATIENTS
New data found treatment with remote pressure monitoring can significantly reduce mortality risk in heart failure patients CardioMEMS is a tiny implantable sensor that can remotely flag early warning signs of worsening heart failure ABBOTT PARK, Ill., March 21, 2023 — Abbott today announced new data that found monitoring patients […]
Sequana Medical announces additional patents for DSR® in China and the United States
Ghent, Belgium – 22 March 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces further strengthening of the intellectual property portfolio for its DSR (Direct Sodium Removal) program. A key composition of matter patent was allowed in China and […]
Aortix Pump Therapy Leads to Rapid Decongestion and Improved Kidney Function in Hospitalized Patients with Heart Failure and Worsening Renal Function
Late-breaking data presented at THT shows substantial fluid loss and improvements in kidney and cardiac function at 30 days after Aortix therapy Cardiorenal syndrome (CRS) is a complex condition that impacts up to 40% of patients with acute decompensated heart failure and is growing at a double-digit rate HOUSTON, March 21, […]
Ancora Heart’s AccuCinch System Demonstrates Significant Improvement in Quality of Life, Cardiac Structure and Function in Heart Failure Patients
12 Month Data Presented as Late-Breaking Clinical Science at THT 2023 and Simultaneously Published in the Journal of Cardiac Failure BOSTON–(BUSINESS WIRE)–Ancora Heart, Inc., a company developing a completely transcatheter device-based therapy to address heart failure (HF), today announced that patients treated with the investigational AccuCinch® Ventricular Restoration System demonstrated improvement […]
Axon Therapies Cohort Study Extends Benefit to 6 months with Early Clinical Data from REBALANCE-HF Randomized Clinical Trial
SANTA CLARA, Calif., March 22, 2023 /PRNewswire/ — Axon Therapies, a private company focused on addressing a root cause of heart failure, today announced positive 6-month results from a roll-in cohort for their feasibility IDE trial, REBALANCE-HF. The latest data is consistent with prior results previously presented for their proprietary Splanchnic Ablation for Volume Management (SAVM) […]



